MIRA designates neuropathic pain as primary indication for Ketamir-2
PremiumThe FlyMIRA designates neuropathic pain as primary indication for Ketamir-2
2M ago
MIRA says it achieves 100% reversal of neuropathic pain with oral Ketamir-2
Premium
The Fly
MIRA says it achieves 100% reversal of neuropathic pain with oral Ketamir-2
3M ago
Mira Pharmaceuticals provides update on preparing IND submission
Premium
The Fly
Mira Pharmaceuticals provides update on preparing IND submission
3M ago
Mira Pharmaceuticals initiated with a Buy at Ascendiant
PremiumThe FlyMira Pharmaceuticals initiated with a Buy at Ascendiant
3M ago
Mira Pharmaceuticals announces insights from additional Ketamir-2 data
Premium
The Fly
Mira Pharmaceuticals announces insights from additional Ketamir-2 data
4M ago
Mira Pharmaceuticals Inc trading resumes
Premium
The Fly
Mira Pharmaceuticals Inc trading resumes
4M ago
Mira Pharmaceuticals announces new results for Ketamir-2
PremiumThe FlyMira Pharmaceuticals announces new results for Ketamir-2
5M ago
Mira Pharmaceuticals reports ‘positive’ results from Ketamir-2 study
Premium
The Fly
Mira Pharmaceuticals reports ‘positive’ results from Ketamir-2 study
5M ago
MIRA Pharmaceuticals Enhances CEO’s Compensation Package
Premium
Company Announcements
MIRA Pharmaceuticals Enhances CEO’s Compensation Package
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100